Leading clinical-stage psychedelic medicine biotech company Mind Medicine Inc. (OTCQB: MMEDF) has published a new set of data on Personalized MDMA Dosing. The study was conducted in the University Hospital Basel Liechti Lab, in Basel, Switzerland.
This research gives first scientific data for predicting responses to MDMA and optimizing dosing using personalized medicine.
This will help in maximizing the potential favorable therapeutic effects while minimizing the adverse effects which occur during treatment of medical conditions.
The research used data from 194 MDMA administered in ten random placebo-controlled studies in healthy subjects by the Liechti Lab.
Extensive data and findings of the research can be accessed from the publisher’s website.